Amgen takes $780M hit to settle kickback charges
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Amgen to lay off 226 in Thousand Oaks
[wikichart align=”right” ticker=”NASDAQ:AMGN” showannotations=”true” livequote=”true” startdate=”19-04-2011″ enddate=”19-10-2011″ width=”300″ height=”245″] Thousand Oaks-based Amgen is laying off 226 people at its headquarters as part of a restructuring of its research operations. Worldwide, the R&D shakeup will affect 380 staff members, but the company’s headquarters are bearing the brunt of the cuts. The company said the layoffs are Read More →
Amgen braces for biosimilars rules
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
PBS Biotech acquires manufacturing firm
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Amgen expects approval for Xgeva as bone treatment in April
Thousand Oaks-based Amgen said Aug. 22 that the U.S. Food and Drug Administration will likely make a decision by April 26, 2012 on the biotech firm’s application to expand the use of its Xgeva bone treatment drug to treat advanced prostate cancer. Amgen, the largest biotech company in the world, said in a statement that Read More →
Brave new biotech: Camarillo startup launches first products
PBS Biotech, a Camarillo-based startup, is bringing its first products to market.
Amgen drug shows blockbuster promise
Putting test results behind the talk at its recent product pipeline review, Thousand Oaks-based Amgen on May 17 released promising results for the Xgeva variant of its potential blockbuster bone drug denosumab.
